Simplex Trading
URGN icon

Simplex Trading’s UroGen Pharma URGN Stock Holding History

Simplex Trading’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Buy
10,500
+100
+1% +$2K ﹤0.01% 4372
2025
Q4 		$244K Sell
10,400
-84,700
-89% -$1.84M ﹤0.01% 4027
2025
Q3 		$1.9M Sell
95,100
-89,800
-49% -$1.61M ﹤0.01% 2381
2025
Q2 		$2.53M Buy
184,900
+177,900
+2,541% +$1.71M ﹤0.01% 1901
2025
Q1 		$77K Sell
7,000
-14,700
-68% -$157K ﹤0.01% 5348
2024
Q4 		$231K Buy
21,700
+20,000
+1,176% +$239K ﹤0.01% 4367
2024
Q3 		$21K Sell
1,700
-11,300
-87% -$168K ﹤0.01% 6652
2024
Q2 		$218K Buy
13,000
+2,200
+20% +$31.3K ﹤0.01% 4576
2024
Q1 		$162K Buy
10,800
+9,300
+620% +$152K ﹤0.01% 5071
2023
Q4 		$22K Sell
1,500
-7,000
-82% -$90.9K ﹤0.01% 6858
2023
Q3 		$119K Buy
8,500
+8,000
+1,600% +$128K ﹤0.01% 4918
2023
Q2 		$5K Sell
500
-1,100
-69% -$12.1K ﹤0.01% 7969
2023
Q1 		$14K Sell
1,600
-900
-36% -$8.28K ﹤0.01% 7269
2022
Q4 		$22K Buy
2,500
+1,000
+67% +$9.47K ﹤0.01% 6798
2022
Q3 		$12K Buy
+1,500
New +$12.4K ﹤0.01% 8100
2022
Q1 		– Sell
-600
Closed -$5K – 11450
2021
Q4 		$5K Buy
+600
New +$8.46K ﹤0.01% 9574
2021
Q1 		– Sell
-4
Closed -$7K – 10106
2020
Q4 		$7K Buy
4
+3
+300% +$63 ﹤0.01% 7615
2020
Q3 		$1K Buy
+1
New +$23 ﹤0.01% 7607
2020
Q2 		– Sell
-103
Closed -$183K – 8412
2020
Q1 		$183K Sell
103
-16
-13% -$432 ﹤0.01% 3709
2019
Q4 		$397K Buy
119
+96
+417% +$2.62K ﹤0.01% 2975
2019
Q3 		$54K Buy
+23
New +$752 ﹤0.01% 4951

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Simplex Trading's URGN Position: Q1 2026 in Review

Simplex Trading reduced its UroGen Pharma (URGN) stake by 64% in Q1 2026, selling an estimated $282K and leaving 8,066 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #4668.

Simplex Trading first reported a position in URGN in Q3 2019 and has held it in 22 quarters since. The position peaked at $2.53M in Q2 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Simplex Trading held 8,066 shares of UroGen Pharma worth $145K as of Q1 2026.
  • Simplex Trading sold 14,043 UroGen Pharma shares in Q1 2026, an estimated $282K.
  • UroGen Pharma made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4668 holding.
  • Simplex Trading first reported a position in UroGen Pharma in Q3 2019 and has held it in 22 quarters since.
  • Simplex Trading's UroGen Pharma position peaked at $2.53M in Q2 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.